Phase II
Harbour BioMed signed an exclusive strategic partnership deal with Sichuan Kelun-Biotech Biopharmaceutical Co. to develop and commercialize an anti-PD-L1 antibody, A167, currently in Phase II development.
Biohaven Pharma, headquartered in New Haven, Conn., announced positive data from a proof-of-concept trial for its BHV-0223 in social anxiety and public speaking anxiety disorders.
Gene therapy has been a dream for many researchers for decades—inserting a healthier gene into patients’ cells to replace defective genes and curing diseases. One disease that would seem to be a good target for gene therapy is hemophilia.
Shares of Realm Therapeutics have plunged more than 50 percent this morning after the company announced its Phase II atopic dermatitis drug failed to distinguish itself from the control arm in the trial.
Western government agencies have been warning of an increase in cyber espionage from nefarious black hats and governments for years. The targets have typically been government and financial installations. But a new warning suggests that biotechnology could be a key target for cyber hackers.
Massachusetts in general and Boston, specifically Cambridge, is one of the two largest centers in the U.S. for biotech startups and life science companies (the other being the San Francisco Bay Area). Here’s a look at 13 Massachusetts life science companies that are showing both gains and losses—mostly gains—at the six-month mark.
Shares of Gemphire Therapeutics have crashed 73 percent in premarket trading after the company revealed its mid-stage non-alcoholic fatty liver disease (NAFLD) treatment for pediatric patients actually worsened the disease in some patients.
Emergent BioSolutions, headquartered in Gaithersburg, Maryland, inked a deal to buy PaxVax, based in Redwood City, California, for $270 million in cash.
Cambridge, Mass.-based Sarepta Therapeutics expanded its gene therapy pipeline up to 11 in an equity deal with Lacerta Therapeutics. Investing $30 million into Alachua, Florida-based Lacerta Therapeutics, Sarepta gained access to the company’s AAV-based CNS-targeted gene therapies.
Shares of Bellerophon Therapeutics have plunged nearly 75 percent this morning after the company announced its Phase III pulmonary arterial hypertension failed to meet endpoints following a pre-specified interim analysis from a Data Monitoring Committee.
PRESS RELEASES